NASOPHARYNGEAL CARCINOMA

This study tests a new treatment for nasopharyngeal cancer that has spread to up to 5 other places in the body. It combines precise radiation (SBRT) with an immunotherapy drug (PD-1 antibody) and chemotherapy. The goal is to see if this approach can control the cancer longer. The…

This study tests whether using smaller radiation targets after chemotherapy can still control cancer while causing fewer long-term side effects. About 445 people with advanced nasopharyngeal cancer will receive standard chemotherapy followed by either standard or reduced radiatio…

This study tests a new drug called BL-B01D1 against standard chemotherapy in people with advanced nasopharyngeal cancer that has not responded to at least two prior treatments. About 386 adults will be randomly assigned to receive either the new drug or a doctor-chosen chemothera…

This early-phase study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, melanoma, and kidney cancer. The main goal is to find a safe dose and understand side effects. About 126 participants will take part to see if the treatm…

This study tests whether specially trained immune cells from healthy donors can safely fight cancers and diseases caused by the Epstein-Barr virus (EBV). The cells are made quickly in the lab and stored in a bank, so they are ready for patients whose cancer has returned or not re…

This study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…

This study tests whether adding the experimental drug KL-A167 to standard chemotherapy (cisplatin and gemcitabine) helps people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer growing. About 295 adults aged 18–75 with confirmed advanced naso…

This early-phase study tests a new drug (DKY709) alone or with another drug (PDR001) in adults with advanced solid tumors like lung cancer, melanoma, and breast cancer that have not responded to standard treatments. The main goal is to check safety and find the right dose. About …

This study tests whether using a smaller area of radiation on the neck is as effective as the standard larger area for treating nasopharyngeal cancer. About 474 patients with early-stage cancer will be randomly assigned to receive either the reduced or conventional radiation. The…

This study tests whether adding a PD-1 inhibitor (a type of immunotherapy) to chemotherapy before standard treatment can help people with advanced nasopharyngeal cancer. About 150 participants will receive either the drug combo or standard care. The main goal is to see if the com…

This study tests whether adding the immunotherapy drug sintilimab to the chemotherapy drug capecitabine can better prevent nasopharyngeal cancer from coming back compared to capecitabine alone. About 150 adults with advanced nasopharyngeal carcinoma who did not respond well to in…

This study tests if wearing pressurized gloves and foot caps during chemotherapy can prevent or reduce nerve damage (tingling, numbness, pain) caused by the drug paclitaxel in people with nasopharyngeal cancer. 182 participants will wear the compression gear on one hand and foot,…

This study looks at the long-term side effects in people who survived nasopharyngeal cancer after radiation and chemotherapy. Researchers will check quality of life, thinking skills, hearing, and hormone levels in 108 survivors who are at least four years past treatment. The goal…